COXTOP 60 60 mg
Etoricoxib
Category: Tablet
Manufacturer: Al-Madina Pharmaceuticals Ltd.
Al-Madina Pharmaceuticals Ltd.
Allopathic
MFG. Licence No. Biological
266
Address
1/1, Tilargati, Tongi, Gazipur
Price: 7.0 ৳
3 x 10 in Blister Pack
Medicine Selling service is not available yet.
Related Medicines
Uses of COXTOP 60:
- Pain relief
Rheumatoid arthritis, Osteoarthritis, Gout
Inflammatory bowel disease, severe congestive heart failure, active peptic ulceration, cerebrovascular disease, CrCL <30 ml/min; lactation. Children and adolescent < 16 yr.
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Etoricoxib is a non-steroidal anti-inflammatory drug (NSAID). It has anti-inflammatory, analgesic and antipyretic activities. Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor.
How to use
Etoricoxib:
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it.
Etoricoxib may be taken with or without food, but it is better to take it at a fixed time.
Administration:
May be taken with or without food.
Adult Dose:
Oral
Osteoarthritis
Adult: 30 mg once daily, increased to 60 mg once daily if needed.
Ankylosing spondylitis; Rheumatoid arthritis
Adult: 90 mg once daily.
Acute gout
Adult: 120 mg once daily. Max duration: 8 days.
Hepatic impairment: Mild (Child-Pugh score of 5-6): 60 mg once daily.
Moderate (Child-Pugh 7-9): Max 60 mg every other day or 30 mg once daily.
Severe (Child-Pugh >10): Avoid.
Child Dose:
Child: <16 yr Contraindicated.
May increase INR w/ oral anticoagulants. May decrease effects of ACE inhibitors, angiotensin II antagonist and diuretics. May increase lithium plasma concentrations. May reduce plasma levels w/ rifampicin. Increased serum concentrations of ethinylestradiol.
Inflammatory bowel disease, severe congestive heart failure, active peptic ulceration, cerebrovascular disease, CrCL <30 ml/min; lactation. Children and adolescent < 16 yr.
Common
- Stomach pain
- Diarrhea
GI disorders; ischemic cardiac events; hypersensitivity reactions, headache, dizziness, nervousness, depression, drowsiness, insomnia, vertigo, tinnitus, photosensitivity; blood disorders, fluid retention, hypertension; dry mouth, taste disturbance, mouth ulcers; appetite and wt changes; chest pain, fatigue, paraesthesia, influenza-like syndrome, myalgia. Renal toxicity.
Etoricoxib should be avoided in late pregnancy because it may cause premature closure of the ductus arteriosus. As it is excreted in breast milk, use of Etoricoxib should be avoided during lactation.
Precaution:
Allergic disorders, coagulation defects; history of cardiac failure, left ventricular dysfunction, hypertension, or in patients with oedema due to other reasons; elderly, renal, cardiac or hepatic impairment. Withdraw treatment if GI lesions develop; caution when admin to dehydrated patients. Regular BP monitoring is advisable. May mask fever and other signs of infection. Pregnancy.
Administration of single doses of Etoricoxib up to 500 mg and multiple doses up to 150 mg/day for 21 days did not result in significant toxicity. In the event of overdose, it is reasonable to employ the usual supportive measures, e.g., remove unabsorbed material from the Gl tract, employ clinical monitoring, and institute supportive therapy, if required.
Store at a temperature of below 30°C, protect from light & moisture. Keep out of reach of children.
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
Etoricoxib is a selective cyclooxygenase-2 (COX-2) inhibitor primarily responsible to reduce mediators of pain and inflammation. Its action is due to inhibition of prostaglandin synthesis via inhibition of COX-2.
The use of Etoricoxib, as with any drug substance known to inhibit COX-2, is not recommended in women attempting to conceive. It is not known whether Etoricoxib is excreted in human milk. Etoricoxib is excreted in the milk of lactating rats. Women who use Etoricoxib must not breastfeed.
Samm Care